After Hours
There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities.
Stocks Info
As a NYSE listed company, DNA falls under the Healthcare sector while operating within the Biotechnology industry segment. The current market capitalization of Ginkgo Bioworks Holdings Inc is $627.12M. A total of 1.9 million shares were traded on the day, compared to an average of 1.19M shares.
In the most recent transaction, Che Austin bought 99 shares of DNA for 10.06 per share on Dec 23 ’24. In a previous transaction on Dec 20 ’24, Che Austin bought 99 shares at 8.42 per share.
Among the insiders who bought shares, Che Austin acquired of 99 shares on Dec 19 ’24 at a per-share price of $9.08. In another insider transaction, Che Austin bought 99 shares at $9.76 per share on Dec 18 ’24.
In spite of price targets being rarely accurate, it tends to exert some kind influence from time to time, and was often accepted by the market as having some value. In terms of 52-week highs and lows, DNA has a high of $74.00 and a low of $5.26.
Balance Sheet Annually/Quarterly
The balance sheet of a company shows what assets and liabilities a company has, as well as the amount, equity investors have invested. With the help of this information, a company’s financial ratios can be calculated to give investors an overview of the company’s prospects. DNA’s latest balance sheet shows that the firm has $1.55B in Cash & Short Term Investments as of fiscal 2021. There were $23.03M in debt and $134.76M in liabilities at the time. Its Book Value Per Share was $15.93, while its Total Shareholder’s Equity was $1.57B.
Analysts Opinion
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for DNA is Buy with a score of 2.17.
